5-甲氧基-3-(1-甲基乙氧基)-2-苯并呋喃羧酸 | 104796-52-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并呋喃
• 中文名称: 5-甲氧基-3-(1-甲基乙氧基)-2-苯并呋喃羧酸
• 英文名称: 5-methoxy-3-(1-methylethoxy)-2-benzofurancarboxylic acid
• 英文别名: 3-isopropyloxy-5-methoxybenzofuran-2-carboxylic acid；5-methoxy-3-propan-2-yloxy-1-benzofuran-2-carboxylic acid
• CAS: 104796-52-3
• 化学式: C₁₃H₁₄O₅
• 分子量: 250.251
• InChiKey: SIMYGTFGOLCCDG-UHFFFAOYSA-N

物化性质

• 熔点：
  138-140 °C(Solv: methanol (67-56-1); water (7732-18-5))
• 沸点：
  390.1±37.0 °C(Predicted)
• 密度：
  1.249±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.9
• 重原子数：
  18
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.31
• 拓扑面积：
  68.9
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  5-甲氧基-3-(1-甲基乙氧基)-2-苯并呋喃羧酸 在 草酰氯 、 N,N-二甲基甲酰胺 作用下， 以 四氢呋喃 为溶剂， 反应 1.75h， 生成 3-Isopropoxy-5-methoxy-benzofuran-2-carbonyl chloride
  参考文献：
  名称：

  苯并[b]噻吩，苯并呋喃，吲哚和萘-2-甲酰胺对E-选择素，ICAM-1和VCAM-1介导的细胞粘附的抑制作用：鉴定PD 144795为抗炎剂。

  摘要：

  以前有报道说，以1，5-甲氧基-3-（1-甲基乙氧基）苯并[b]噻吩-2-羧酰胺为例的3-烷氧基苯并[b]噻吩-2-甲酰胺降低了中性粒细胞对活化内皮细胞的粘附通过抑制内皮细胞表面粘附分子E-选择素和ICAM-1的上调。该发现在这里扩展到一系列的3-硫代苯并[b]噻吩-2-羧酰胺以及1的杂环类似物，包括苯并呋喃，吲哚和萘。抑制E-选择蛋白和ICAM-1表达的化合物对VCAM-1的表达具有相同的作用。PD 144795，亚砜类似物1，即5-甲氧基-3-（1-甲基乙氧基）苯并[b]噻吩-2-羧酰胺1-氧化物（44）在几种炎症模型中具有口服活性。

  DOI：

  10.1021/jm00022a026
• 作为产物：
  描述：

  (hydroxy-3 methoxy-5 benzofuryl-2)-carboxylate de methyle 在 氢氧化钾 、 potassium tert-butylate 作用下， 以 甲醇 、 二甲基亚砜 为溶剂， 反应 10.0h， 生成 5-甲氧基-3-(1-甲基乙氧基)-2-苯并呋喃羧酸
  参考文献：
  名称：

  Novel benzothiophene-, benzofuran-, and naphthalenecarboxamidotetrazoles as potential antiallergy agents

  摘要：

  The synthesis and antiallergic activity of a series of novel benzothiophene-, benzofuran-, and naphthalenecarbox-amidotetrazoles are described. A number of the compounds inhibit the release of histamine from anti-IgE stimulated basophils obtained from allergic donors. Optimal inhibition is exhibited in benzothiophenes with a 3-alkoxy substituent in combination with a 5-methoxy, 6-methoxy, or a 5,6-dimethoxy group. Compounds 13c (CI-959) also inhibited respiratory burst of human neutrophils and the release of mediators from anti-IgE-stimulated human chopped lung.

  DOI：

  10.1021/jm00083a023

文献信息

• 3-thio or amino substituted-benzo[b]thiophene-2-carboxamides and
  申请人：Warner-Lambert Company

  公开号：US05350748A1

  公开（公告）日：1994-09-27

  3-Thio or amino substituted benzo[b]thiophene-2-carboxamides and 3-oxygen, thio, or amino substituted benzofuran-2-carboxamides are described as agents which inhibit leukocyte adherence to vascular endothelium and, as such, are effective therapeutic agents for treating inflammatory diseases. Certain of these compounds are novel and methods of manufacture are also described. The same benzo[b]thiophene and benzofuran-2-carboxamides also inhibit the activation of human immunodeficiency virus (HIV), latent in infected mammals.

  3-硫代或氨基取代的苯并[b]噻吩-2-羧酰胺和3-氧、硫或氨基取代的苯并呋喃-2-羧酰胺被描述为抑制白细胞粘附于血管内皮的药剂，并因此是治疗炎症性疾病的有效治疗药剂。其中某些化合物是新颖的，还描述了其制造方法。同样的苯并[b]噻吩和苯并呋喃-2-羧酰胺也抑制人类免疫缺陷病毒（HIV）在感染的哺乳动物中的潜伏活化。
• Synthesis and Cannabinoid Activity of a Variety of 2,3-Substituted 1-Benzo[b]thiophen Derivatives and 2,3-Substituted Benzofuran: Novel Agonists for the CB1 Receptor
  作者：Gerard P. Moloney、James A. Angus、Alan D. Robertson、Martin J. Stoermer、Michael Robinson、Lucy Lay、Christine E. Wright、Ken McRae、Arthur Christopoulos

  DOI：10.1071/ch07412

  日期：——

  have discovered a novel series of compounds, which contain a 1-benzo[b]thiophen or a benzofuran group as the central aromatic group. Our investigation of this series of compounds has enhanced our understanding of the importance of binding sites within the CB1 receptor for favourable CB1 potency. Our understanding of these factors allowed us to modify the structure of a 1-benzothiophen derivative and improve

  已经进行了探索性的化学努力，以开发一系列新的化合物作为选择性 CB1 激动剂。希望这种类型的化合物在中风或颅脑外伤后的疼痛控制和脑缺血方面具有临床应用价值。我们在此报告旨在研究几类 1-苯并[b]噻吩和苯并呋喃衍生物作为新型 CB1 激动剂的药物化学研究。我们发现了一系列新的化合物，其中包含一个 1-苯并[b]噻吩或苯并呋喃基团作为中心芳族基团。我们对这一系列化合物的研究增强了我们对 CB1 受体内结合位点对有利 CB1 效力的重要性的理解。
• Benzothiophenes and benzofurans and antiallergic use thereof
  申请人：Warner-Lambert Company

  公开号：US04703053A1

  公开（公告）日：1987-10-27

  Novel benzothiophene and benzofuran derivatives having antiallergic activity are described as well as a method of manufacture, pharmaceutical compositions, and methods of use therefor. The disclosure describes the use of derivatives for prevention of the release of mediators including histamine and leukotrienes from basophils and mast cells, and prevent respiratory burst in neutrophils providing activity useful in cardiovascular disorders as well as in antiinflammatory, psoriasis, and antimigraine treatment.

  描述了具有抗过敏活性的新型苯并噻吩和苯并呋喃衍生物，以及其制备方法、药物组合物和使用方法。该公开内容描述了衍生物的用途，用于预防嗜碱细胞和肥大细胞释放组胺和白三烯等介质，并防止中性粒细胞的呼吸爆发，提供在心血管疾病以及抗炎、银屑病和抗偏头痛治疗中有用的活性。
• Inhibition of adhesion molecule expression by N-alkylthiopyridine-benzo[b]thiophene-2-carboxamides
  作者：Diane H. Boschelli、David T. Connor、Mark E. Lesch、Denis J. Schrier

  DOI：10.1016/0968-0896(96)00046-6

  日期：1996.4

  The surface levels of ICAM-1 and E-selectin on activated endothelial cells can be reduced by 3-alkoxybenzo[b]thiophene-2-carboxamides. This property is shared by several N-alkylthiopyridine substituted imides. Combining structural elements of these two diverse series lead to a new class of small molecule inhibitors of adhesion molecule expression.

  3-烷氧基苯并[b]噻吩-2-羧酰胺可降低活化的内皮细胞上ICAM-1和E-选择素的表面水平。该性质由几个N-烷基硫代吡啶取代的酰亚胺共享。这两个不同系列的结构元素的组合导致了一类新的粘附分子表达的小分子抑制剂。
• Branched chain amino acid-dependent aminotransferase inhibitors and their use in the treatment of neurodegenerative diseases
  申请人：Bora Martin Keenan

  公开号：US20050004167A1

  公开（公告）日：2005-01-06

  The invention relates to BCAT inhibitor compounds of formula (I) and use thereof for treating or preventing neuronal loss associated with stroke, ischemia, CNS trauma, hypoglycemia and surgery, as well as treating neurodegenerative diseases including Alzheimer's disease, amyotrophic lateral sclerosis, Huntington's disease and Down's syndrome, treating or preventing the adverse consequences of the overstimulation of the excitatory amino acids, treating anxiety, psychosis, convulsions, aminoglycoside antibiotics-induced hearing loss, migraine headache, chronic pain, neuropathic pain, Parkinson's disease, diabetic retinopathy, glaucoma, CMV retinitis, urinary incontinence, opioid tolerance or withdrawal, and inducing anesthesia, as well as for enhancing cognition.

  本发明涉及公式（I）的BCAT抑制剂化合物及其用于治疗或预防与中风、缺血、中枢神经系统创伤、低血糖和手术相关的神经元丢失，以及治疗神经退行性疾病，包括阿尔茨海默病、肌萎缩性侧索硬化症、亨廷顿病和唐氏综合症，治疗或预防兴奋性氨基酸过度刺激的不良后果，治疗焦虑、精神病、惊厥、氨基糖苷类抗生素引起的听力损失、偏头痛、慢性疼痛、神经病性疼痛、帕金森病、糖尿病视网膜病变、青光眼、巨细胞病毒性视网膜炎、尿失禁、阿片类耐受或戒断，以及诱导麻醉和增强认知功能。